TY - JOUR
T1 - Survival in small cell lung carcinoma is independent of bcl-2 expression
AU - Maitra, Anirban
AU - Amirkhan, Robin H.
AU - Saboorian, M. Hossein
AU - Frawley, William H.
AU - Ashfaq, Raheela
PY - 1999/6
Y1 - 1999/6
N2 - Bcl-2 overexpression is a common event in small cell carcinomas (SCLC). The bcl-2 oncoprotein has a unique oncogenic role by inhibiting programmed cell death (apoptosis), resulting in tumorigenesis and chemoresistance. Forty-two cases of SCLC were stained immunohistochemically with bcl-2 monoclonal antibody (Biogenex, San Ramon, CA) after using an antigen retrieval step with citrate buffer, bcl-2 positivity was determined as detection of the oncoprotein in greater than 10% of noncrushed neoplastic cells. Twenty-five of 42 (60%) patients had extensive disease at presentation, 10 of 42 (24%) had limited disease, and 7 of 42 (16%) had disease localized to the lung. Twenty-four of 42 (57%) tumors were bcl-2 positive, and 18 of 42 (43%) tumors were bcl-2 negative. Follow-up in patients ranged from 7 days to 96 months (mean follow-up, 20 months). The median survival of patients with bcl-2-positive tumors was 11 months, as opposed to 13 months for bcl-2-negative tumors. There was no significant difference in median survival between bcl-2-positive and bcl-2-negative SCLC (log rank test, P = .2256). Using Cox's proportional hazards model, median survival in SCLC was determined to be independent of age at diagnosis, stage at presentation, therapeutic modality, and bcl-2 expression, bcl-2 expression does not significantly influence survival in SCLC.
AB - Bcl-2 overexpression is a common event in small cell carcinomas (SCLC). The bcl-2 oncoprotein has a unique oncogenic role by inhibiting programmed cell death (apoptosis), resulting in tumorigenesis and chemoresistance. Forty-two cases of SCLC were stained immunohistochemically with bcl-2 monoclonal antibody (Biogenex, San Ramon, CA) after using an antigen retrieval step with citrate buffer, bcl-2 positivity was determined as detection of the oncoprotein in greater than 10% of noncrushed neoplastic cells. Twenty-five of 42 (60%) patients had extensive disease at presentation, 10 of 42 (24%) had limited disease, and 7 of 42 (16%) had disease localized to the lung. Twenty-four of 42 (57%) tumors were bcl-2 positive, and 18 of 42 (43%) tumors were bcl-2 negative. Follow-up in patients ranged from 7 days to 96 months (mean follow-up, 20 months). The median survival of patients with bcl-2-positive tumors was 11 months, as opposed to 13 months for bcl-2-negative tumors. There was no significant difference in median survival between bcl-2-positive and bcl-2-negative SCLC (log rank test, P = .2256). Using Cox's proportional hazards model, median survival in SCLC was determined to be independent of age at diagnosis, stage at presentation, therapeutic modality, and bcl-2 expression, bcl-2 expression does not significantly influence survival in SCLC.
KW - Bcl-2
KW - Lung cancer
KW - Small cell
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=0033025610&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033025610&partnerID=8YFLogxK
U2 - 10.1016/S0046-8177(99)90099-0
DO - 10.1016/S0046-8177(99)90099-0
M3 - Article
C2 - 10374782
AN - SCOPUS:0033025610
SN - 0046-8177
VL - 30
SP - 712
EP - 717
JO - Human Pathology
JF - Human Pathology
IS - 6
ER -